GLP-1s Are Not Just a Weight Loss Story
GLP-1 medications are being studied for effects that may extend beyond weight loss, including cardiometabolic outcomes and behavior-related pathways.
18 min readRead->
Medicine
Obesity
Obesity medicine, metabolic health, stigma-aware consumer education, cardiometabolic risk, and treatment context.
1 published articleBuilding this topic
Related research
STEP 1: Once-weekly semaglutide in adults with overweight or obesitySTEP 5: Two-year effects of semaglutide in adults with overweight or obesitySELECT: Semaglutide and cardiovascular outcomes in obesity without diabetesSTEP-HFpEF: Semaglutide in patients with heart failure with preserved ejection fraction and obesitySURMOUNT-1: Tirzepatide once weekly for the treatment of obesity
Useful source library entries
FDA approves Wegovy to reduce risk of serious heart problems in adults with obesity or overweight and cardiovascular diseaseFDA approves Zepbound as first medication for obstructive sleep apnea in adults with obesityOnce-weekly semaglutide in adults with overweight or obesitySTEP 1 semaglutide obesity trialTwo-year effects of semaglutide in adults with overweight or obesity
Related topics
Vital Signals
Get the weekly health signal without the wellness fog.
A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.
No spam. No miracle claims. Just better health signal.
By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.